Lyell Immunopharma Inc
LYEL35.090USD
-3.510-9.09%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
677.03MMarket Cap
LossP/E TTM
More Details of Lyell Immunopharma Inc Company
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Lyell Immunopharma Inc Info
Ticker SymbolLYEL
Company nameLyell Immunopharma Inc
IPO dateJun 17, 2021
CEOSeely (Lynn)
Number of employees300
Security typeOrdinary Share
Fiscal year-endJun 17
Address201 Haskins Way
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16506950677
Websitehttps://lyell.com/
Ticker SymbolLYEL
IPO dateJun 17, 2021
CEOSeely (Lynn)
Company Executives of Lyell Immunopharma Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Lynn Seely, M.D.
Dr. Lynn Seely, M.D.
President, Chief Executive Officer, Interim Principal Financial Officer, Director
President, Chief Executive Officer, Interim Principal Financial Officer, Director
40.28K
-1.01%
Dr. Sumant Ramachandra, M.D., Ph.D.
Dr. Sumant Ramachandra, M.D., Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
1.78K
--
Dr. Mark Bachleda
Dr. Mark Bachleda
Director
Director
--
--
Dr. Richard D. Klausner, M.D.
Dr. Richard D. Klausner, M.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. Stephen Hill
Mr. Stephen Hill
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William J. (Bill) Rieflin
Mr. William J. (Bill) Rieflin
Independent Director
Independent Director
--
--
Dr. Gary Lee, Ph.D.
Dr. Gary Lee, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
--
--
Ms. Catherine (Cathy) Friedman
Ms. Catherine (Cathy) Friedman
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Lynn Seely, M.D.
Dr. Lynn Seely, M.D.
President, Chief Executive Officer, Interim Principal Financial Officer, Director
President, Chief Executive Officer, Interim Principal Financial Officer, Director
40.28K
-1.01%
Dr. Sumant Ramachandra, M.D., Ph.D.
Dr. Sumant Ramachandra, M.D., Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
1.78K
--
Dr. Mark Bachleda
Dr. Mark Bachleda
Director
Director
--
--
Dr. Richard D. Klausner, M.D.
Dr. Richard D. Klausner, M.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. Stephen Hill
Mr. Stephen Hill
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARCH Venture Partners
12.99%
Innovative Cellular Therapeutics Holdings Ltd
8.94%
GSK plc
7.12%
Foresite Capital Management, LLC
6.01%
Gates Frontier, L.L.C.
4.90%
Other
60.03%
Shareholders
Shareholders
Proportion
ARCH Venture Partners
12.99%
Innovative Cellular Therapeutics Holdings Ltd
8.94%
GSK plc
7.12%
Foresite Capital Management, LLC
6.01%
Gates Frontier, L.L.C.
4.90%
Other
60.03%
Shareholder Types
Shareholders
Proportion
Corporation
26.12%
Investment Advisor
19.41%
Venture Capital
17.36%
Private Equity
8.49%
Hedge Fund
3.35%
Individual Investor
1.52%
Investment Advisor/Hedge Fund
1.19%
Pension Fund
0.14%
Research Firm
0.11%
Other
22.31%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
260
9.93M
51.69%
-303.37K
2025Q2
273
11.42M
73.88%
-621.28K
2025Q1
284
16.50M
76.82%
-316.09K
2024Q4
285
234.38M
80.23%
+17.13M
2024Q3
284
205.56M
78.25%
-10.65M
2024Q2
276
225.77M
86.93%
-4.87M
2024Q1
265
225.53M
87.01%
-3.27M
2023Q4
256
223.66M
89.04%
+190.31K
2023Q3
246
214.93M
85.87%
-13.13M
2023Q2
244
214.42M
85.94%
-10.26M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARCH Venture Partners
1.82M
9.48%
-2.00
-0.00%
Jun 30, 2025
GSK plc
1.51M
7.87%
--
--
Mar 31, 2025
Foresite Capital Management, LLC
1.21M
6.28%
-1.00
-0.00%
Jun 30, 2025
Gates Frontier, L.L.C.
1.04M
5.42%
+1.04M
--
Jul 25, 2025
Explore Investments LLC
1.04M
5.42%
+1.04M
--
Jul 25, 2025
MWG Management, Ltd.
1.01M
5.25%
-1.00
-0.00%
Jun 30, 2025
The Vanguard Group, Inc.
442.63K
2.3%
-44.26K
-9.09%
Jun 30, 2025
Orland Properties Ltd
754.70K
3.93%
--
--
Jun 30, 2025
Decheng Capital LLC
595.47K
3.1%
-1.00
-0.00%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Biotechnology ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
Humankind US Stock ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
Hypatia Women CEO ETF
0%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Humankind US Stock ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Hypatia Women CEO ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 28, 2025
Merger
20→1
Date
Type
Ratio
May 28, 2025
Merger
20→1
FAQs
Who are the top five shareholders of Lyell Immunopharma Inc?
The top five shareholders of Lyell Immunopharma Inc are:
ARCH Venture Partners holds 1.82M shares, accounting for 9.48% of the total shares.
GSK plc holds 1.51M shares, accounting for 7.87% of the total shares.
Foresite Capital Management, LLC holds 1.21M shares, accounting for 6.28% of the total shares.
Gates Frontier, L.L.C. holds 1.04M shares, accounting for 5.42% of the total shares.
Explore Investments LLC holds 1.04M shares, accounting for 5.42% of the total shares.
ARCH Venture Partners holds 1.82M shares, accounting for 9.48% of the total shares.
GSK plc holds 1.51M shares, accounting for 7.87% of the total shares.
Foresite Capital Management, LLC holds 1.21M shares, accounting for 6.28% of the total shares.
Gates Frontier, L.L.C. holds 1.04M shares, accounting for 5.42% of the total shares.
Explore Investments LLC holds 1.04M shares, accounting for 5.42% of the total shares.
What are the top three shareholder types of Lyell Immunopharma Inc?
The top three shareholder types of Lyell Immunopharma Inc are:
ARCH Venture Partners
Innovative Cellular Therapeutics Holdings Ltd
GSK plc
ARCH Venture Partners
Innovative Cellular Therapeutics Holdings Ltd
GSK plc
How many institutions hold shares of Lyell Immunopharma Inc (LYEL)?
As of 2025Q3, 260 institutions hold shares of Lyell Immunopharma Inc, with a combined market value of approximately 9.93M, accounting for 51.69% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -22.18%.
What is the biggest source of revenue for Lyell Immunopharma Inc?
In --, the -- business generated the highest revenue for Lyell Immunopharma Inc, amounting to -- and accounting for --% of total revenue.
